The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the healthcare system and physical activity behaviours including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

Graphical abstract

中文翻译：

---

2 型糖尿病高血糖的管理，2022 年。美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 的共识报告

美国糖尿病协会和欧洲糖尿病研究协会召集了一个小组，更新了之前关于成人 2 型糖尿病高血糖管理的共识声明，该声明自 2006 年发布，最后更新于 2019 年。目标受众是全谱在美国和欧洲提供糖尿病护理的专业医疗团队。自 2018 年以来对出版物的系统检查为新建议提供了依据。其中包括对健康的社会决定因素、医疗保健系统和身体活动行为（包括睡眠）的额外关注。作为糖尿病管理整体方法的一部分，人们更加重视体重管理。涉及钠-葡萄糖协同转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管和肾脏结局试验的结果，包括亚组评估，为心肾疾病高危糖尿病患者的心肾保护提供了更广泛的建议。在汇总列出共识建议后，提供了实用的实施技巧。

图形概要